GSK Buys Pulmonary Hypertension Drug in $950M Deal; Alkermes CEO Retires; Novo Expands Oral Peptides
GSK acquires pulmonary hypertension drug from 35Pharma in a $950 million deal. Alkermes CEO Richard Pops will retire, and Novo is expanding its oral peptide pipeline.
· 100d ago
